Diversify Advisory Services LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,991 shares of the biotechnology company's stock, valued at approximately $332,000.
A number of other institutional investors have also added to or reduced their stakes in ASND. HighTower Advisors LLC acquired a new position in Ascendis Pharma A/S during the fourth quarter worth $484,000. Corient Private Wealth LLC bought a new stake in Ascendis Pharma A/S during the fourth quarter worth about $450,000. American Century Companies Inc. lifted its position in Ascendis Pharma A/S by 17.5% during the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock worth $56,072,000 after purchasing an additional 60,548 shares during the period. LPL Financial LLC lifted its position in Ascendis Pharma A/S by 60.1% during the fourth quarter. LPL Financial LLC now owns 4,199 shares of the biotechnology company's stock worth $578,000 after purchasing an additional 1,577 shares during the period. Finally, Artisan Partners Limited Partnership lifted its position in Ascendis Pharma A/S by 0.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after purchasing an additional 39,309 shares during the period.
Ascendis Pharma A/S Stock Down 0.5%
Shares of NASDAQ ASND traded down $0.83 during trading on Thursday, reaching $169.31. The company had a trading volume of 147,974 shares, compared to its average volume of 482,383. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $183.00. The stock has a market cap of $10.35 billion, a PE ratio of -26.80 and a beta of 0.38. The business's 50-day moving average is $169.96 and its 200 day moving average is $155.16.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. On average, analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. increased their target price on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. Oppenheimer reissued an "outperform" rating and set a $224.00 target price (up previously from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Wedbush raised their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada increased their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and a consensus price target of $223.07.
View Our Latest Stock Report on ASND
Ascendis Pharma A/S Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading

Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.